You're describing a compound that has a complex chemical name. Let's break it down and discuss its potential importance:
**Understanding the Compound:**
* **1-(4-methoxyphenyl)-3-[[oxo(thiophen-2-yl)methyl]amino]thiourea:** This is the full IUPAC name of the compound.
* **Structure:** The compound consists of:
* **Thiourea:** A central unit with a sulfur atom and two amino groups.
* **4-methoxyphenyl:** A phenyl ring (a six-membered carbon ring) with a methoxy group (-OCH3) attached. This part contributes aromatic character.
* **Thiophen-2-yl:** A five-membered ring containing sulfur (thiophene) with a carbonyl group (C=O) attached.
* **[oxo(thiophen-2-yl)methyl]amino:** An amino group linked to a carbon attached to both a carbonyl group and a thiophen-2-yl group.
**Potential Importance for Research:**
This compound, with its unique structure, could be potentially important for several research areas:
1. **Medicinal Chemistry:**
* **Drug Discovery:** The presence of thiourea and aromatic groups makes it a good candidate for exploring potential biological activity. Many thioureas are known to exhibit diverse pharmacological properties, including anti-inflammatory, anti-microbial, and anti-cancer activities.
* **Drug Development:** The compound's structure could be modified and optimized to enhance its activity and selectivity for specific targets.
2. **Materials Science:**
* **Organic Electronics:** The compound's aromatic system and sulfur-containing groups could make it suitable for applications in organic electronics like organic light-emitting diodes (OLEDs) or solar cells.
3. **Analytical Chemistry:**
* **Spectroscopy:** The compound's structure, particularly the sulfur and carbonyl groups, could lead to unique spectroscopic properties, potentially making it useful as a probe or marker in analytical methods.
**Key Points to Consider:**
* **Synthesis:** To study this compound, researchers would need to synthesize it. This could involve several synthetic steps and careful optimization.
* **Biological Activity:** While the compound has potential, its actual biological activity needs to be investigated experimentally. It would need to be tested against a variety of targets and cells.
* **Toxicity:** Before any potential medicinal applications, the compound's toxicity and safety profile would need to be thoroughly assessed.
**In conclusion:** 1-(4-methoxyphenyl)-3-[[oxo(thiophen-2-yl)methyl]amino]thiourea is a complex compound with potential for exploration in diverse research fields. Its actual importance will depend on the results of future research and development.
ID Source | ID |
---|---|
PubMed CID | 848930 |
CHEMBL ID | 1323624 |
CHEBI ID | 107560 |
SCHEMBL ID | 8044717 |
Synonym |
---|
n-(4-methoxyphenyl)-2-(2-thienylcarbonyl)hydrazinecarbothioamide |
AO-476/41839681 |
smr000229543 |
MLS000706018 |
zinc00383353 , |
CHEBI:107560 |
1-(4-methoxyphenyl)-3-(thiophene-2-carbonylamino)thiourea |
HMS2512N07 |
n1-(4-methoxyphenylaminothiocarbonyl)-n2-(thien-2-carbonyl)hydrazine |
CDMJIFSWLUXAQT-UHFFFAOYSA-N , |
CHEMBL1323624 |
SCHEMBL8044717 |
1-(4-methoxyphenyl)-3-[[oxo(thiophen-2-yl)methyl]amino]thiourea |
Q27185885 |
n-(4-methoxyphenyl)-2-(thiophene-2-carbonyl)hydrazinecarbothioamide |
Class | Description |
---|---|
methoxybenzenes | Any aromatic ether that consists of a benzene skeleton substituted with one or more methoxy groups. |
substituted aniline | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 1.4125 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
Niemann-Pick C1 disease protein, partial | Homo sapiens (human) | Potency | 30.7693 | 0.6284 | 10.8054 | 25.0177 | AID720526; AID720527 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 17.3457 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 0.7079 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 39.8107 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 49.9169 | 0.0126 | 2.4518 | 25.0177 | AID493203 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 23.9372 | 0.0002 | 2.6215 | 31.4954 | AID485297; AID493200; AID624116; AID624493; AID624501; AID720525; AID720528 |
geminin | Homo sapiens (human) | Potency | 6.5131 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
Vpr | Human immunodeficiency virus 1 | Potency | 11.2202 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
lamin isoform A-delta10 | Homo sapiens (human) | Potency | 35.4813 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 3.5481 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 35.4813 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
intracellular non-membrane-bounded organelle | TAR DNA-binding protein 43 | Homo sapiens (human) |
nucleus | TAR DNA-binding protein 43 | Homo sapiens (human) |
nucleoplasm | TAR DNA-binding protein 43 | Homo sapiens (human) |
perichromatin fibrils | TAR DNA-binding protein 43 | Homo sapiens (human) |
mitochondrion | TAR DNA-binding protein 43 | Homo sapiens (human) |
cytoplasmic stress granule | TAR DNA-binding protein 43 | Homo sapiens (human) |
nuclear speck | TAR DNA-binding protein 43 | Homo sapiens (human) |
interchromatin granule | TAR DNA-binding protein 43 | Homo sapiens (human) |
nucleoplasm | TAR DNA-binding protein 43 | Homo sapiens (human) |
chromatin | TAR DNA-binding protein 43 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |